Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung CancerHeather A. Wakelee, Jonathan Spicer, Shugeng Gao et al.|New England Journal of Medicine|2023Cited by 1k
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trialMary O’Brien, Solange Peters, Luis Paz‐Ares et al.|The Lancet Oncology|2022Cited by 738
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trialJonathan Spicer, Marina Chiara Garassino, Heather A. Wakelee et al.|The Lancet|2024Cited by 233